## Abstract Deletion of the long arm of chromosome 6 (6q) frequently occurs in many neoplasms, including carcinomas of the prostate and breast and melanoma, suggesting the location of a tumor‐suppressor gene or genes at 6q. At present, however, the region of deletion has not been well defined, and
Defining a common region of deletion at 13q21 in human cancers
✍ Scribed by Ceshi Chen; Will W. Brabham; Brian G. Stultz; Henry F. Frierson Jr; J. Carl Barrett; Charles L. Sawyers; John T. Isaacs; Jin-Tang Dong
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 337 KB
- Volume
- 31
- Category
- Article
- ISSN
- 1045-2257
- DOI
- 10.1002/gcc.1152
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Previous molecular genetic analyses identified a region of deletion at 13q21 in a variety of human cancers, suggesting the existence of a tumor suppressor gene(s) at this locus. In our earlier study on prostate cancer, the region of deletion was confined to a 3.1 cM interval between D13S152 and D13S162. At present, however, no known gene located in this interval has been firmly implicated in cancer, and the region remains too large for gene identification. To fine‐map the area of interest, we established a contig of bacterial artificial chromosome (BAC) clones, narrowed the region of deletion by loss of heterozygosity (LOH) and homozygosity‐mapping‐of‐deletion (HOMOD) analyses in different types of cancers, and tested a candidate gene from the region for mutation and alteration of expression in prostate cancers. The contig consisted of 75 overlapping BAC clones. In addition to the generation of 47 new sequence‐tagged‐site (STS) markers from the ends of BAC inserts, 76 known STS and expressed sequence tag markers were mapped to the contig (25 kb per marker on average). The minimal region of deletion was further defined to be about 700 kb between markers D13S791 and D13S166 by LOH analysis of 42 cases of prostate cancer, and by HOMOD analysis of eight prostate cancer cell lines/xenografts and 49 cell lines from cancers of the breast, ovary, endometrium, and cervix, using 18 microsatellite markers encompassing the deletion region. A gene that is homologous to the WT1 tumor suppressor gene, AP‐2rep (KLF12), was mapped in this region and was analyzed for its expression and genetic mutation. In addition to low levels of expression in both normal and neoplastic cells of the prostate, this gene did not have any mutations in a group of aggressive prostate cancers and cell lines/xenografts, as assessed by the methods of polymerase chain reaction‐single strand conformational polymorphism analysis and direct sequencing. These studies suggest that a 700 kb interval at 13q21 harbors a tumor suppressor gene(s) that seems to be involved in multiple types of cancer, and that the AP‐2rep gene is unlikely to be an important tumor suppressor gene in prostate cancer. The BAC contig and high‐resolution physical map of the defined region of deletion should facilitate the cloning of a tumor suppressor gene(s) at 13q21. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Frequent allelic losses on chromosome arm 13q are observed in carcinomas of the head and neck, breast, ovary, and pituitary gland. We analyzed 59 primary prostate tumors (stage B, 18 patients; C, 12 patients; D1, 4 patients; and endocrine therapy-resistant cancer death, 25 patients), as well as 18 m
Loss of heterozygosity for chromosome 22 (LOH 22) occurs in gliomas of all malignancy grades. Neurofibromatosis type 2 (NF2) patients are at increased risk of developing a glioma. However, the NF2 gene in 22q12.2 is not involved in glioma tumorigenesis. To detect additional regions on chromosome 22
Chromosome 13 is one of the most frequently altered chromosomes in cancer, including carcinoma of the prostate. Two known tumor suppressor genes, RB1 and BRCA2, map to chromosome 13; however, recent reports suggest that unknown genes on 13q are more likely to be involved in the development of prosta
## Abstract The frequent presence of loss of heterozygosity (LOH) at 21q21 in lung cancer suggests the existence of putative tumor suppressor genes in this genomic region. Furthermore, the identification of a homozygous deletion in this region has lent further support for its potential involvement
## Background: We analyzed loss of heterozygosity (loh) in 54 primary neuroblastomas (nbs) using 12 microsatellite markers on 14q32, and found that 31% (17/54) nbs showed loh. ## Procedure: The smallest region of overlap (sro) was identified between d14s62 and d14s987. ## Results: There was no